-
Ibritumomab tiuxetan (pronounced /ɪbrɪˈtuːmoʊmæb taɪˈʌksɛtæn/), sold
under the
trade name Zevalin, is a
monoclonal antibody radioimmunotherapy treatment...
- 2002, the
United States Food and Drug
Administration (FDA)
approved ibritumomab tiuxetan (Zevalin),
which is an anti-CD20
monoclonal antibody conjugated...
- A
radioligand is a
microscopic particle which consists of a
therapeutic radioactive isotope and the cell-targeting
compound - the ligand. The
ligand is...
-
Monoclonal antibody ibritumomab conjugated with tiuxetan...
-
antibody specific for CD20,
developed from its
parent antibody Ibritumomab. As with
ibritumomab,
rituximab targets CD20,
making it
effective in
treating certain...
-
radioisotope yttrium-90 (90Y) is used to
label drugs such as
edotreotide and
ibritumomab tiuxetan for the
treatment of
various cancers,
including lymphoma, leukemia...
- Tositumomab/iodine (131I)
tositumomab V10XX01
Sodium phosphate (32P) V10XX02
Ibritumomab tiuxetan (90Y) V10XX03
Radium (223Ra)
dichloride V10XX04
Lutetium (177Lu)...
-
target of the mAbs rituximab, ocrelizumab, obinutuzumab, ofatumumab,
ibritumomab tiuxetan, tositumomab, and ublituximab,
which are all
active agents in...
-
neoplasm or is not
accessible in
normal cells. 131I
tositumomab and 90Y
ibritumomab tiuxetan were the
first agents of radioimmunotherapy, and they were approved...
- radiosynthesis/
radiolabeling process,
which is
tailored to the
desired product.
Ibritumomab Tiuxetan;
Zevalin - For
dosimetry estimates prior to 90Y immunotherapy...
